...
首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing.
【24h】

Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing.

机译:弥漫性大B细胞淋巴瘤使用全基因组测序的突变与结构分析。

获取原文
获取原文并翻译 | 示例

摘要

Diffuse large B-cell lymphoma (DLBCL) is a genetically heterogeneous cancer composed of at least 2 molecular subtypes that differ in gene expression and distribution of mutations. Recently, application of genome/exome sequencing and RNA-seq to DLBCL has revealed numerous genes that are recurrent targets of somatic point mutation in this disease. Here we provide a whole-genome-sequencing-based perspective of DLBCL mutational complexity by characterizing 40 de novo DLBCL cases and 13 DLBCL cell lines and combining these data with DNA copy number analysis and RNA-seq from an extended cohort of 96 cases. Our analysis identified widespread genomic rearrangements including evidence for chromothripsis as well as the presence of known and novel fusion transcripts. We uncovered new gene targets of recurrent somatic point mutations and genes that are targeted by focal somatic deletions in this disease. We highlight the recurrence of germinal center B-cell-restricted mutations affecting genes that encode the S1P receptor and 2 small GTPases (GNA13 and GNAI2) that together converge on regulation of B-cell homing. We further analyzed our data to approximate the relative temporal order in which some recurrent mutations were acquired and demonstrate that ongoing acquisition of mutations and intratumoral clonal heterogeneity are common features of DLBCL. This study further improves our understanding of the processes and pathways involved in lymphomagenesis, and some of the pathways mutated here may indicate new avenues for therapeutic intervention.
机译:弥漫性大B细胞淋巴瘤(DLBCL)是由至少2个分子亚型组成的遗传异质癌,其在基因表达和突变分布中不同。最近,基因组/外壳测序和RNA-SEQ至DLBCL的应用揭示了许多基因,即该疾病中的体细胞点突变的复发靶标。在这里,我们通过表征40 de Novo DLBCL病例和13个DLBCL细胞系,并将这些数据与DNA拷贝数分析和RNA-SEQ与96例的扩展队列组合这些数据,提供了基于DLBCL突变复杂性的全基因组测序的视角。我们的分析确定了广泛的基因组重排,包括Chromothripsis的证据以及已知和新的融合转录物的存在。我们发现了通过该疾病中局灶性体细胞缺失靶向的复发体细胞点突变和基因的新基因靶标。我们突出了发射生发中心B细胞限制突变的复发,影响编码S1P受体的基因和2个小GTP酶(GNA13和GNAi2),其在一起会聚在B细胞归巢的调节。我们进一步分析了我们的数据,以近似获得一些复发突变的相对时间顺序,并证明正在进行的突变和肿瘤内克隆异质性是DLBCL的常见特征。本研究进一步提高了我们对淋巴瘤中所涉及的过程和途径的理解,这里一些突变的途径可能表示用于治疗干预的新途径。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号